Cardiac late effects are responsible for a significant burden of mortality and morbidity among pediatric Hodgkin's lymphoma (HL) survivors (HLS). The aim of our study was to assess clinical and subclinical cardiac sequelae in a cohort of childhood HLS treated in the 1980s with doxorubicin, bleomycin, vinblastine, and dacarbazine (the ABVD regimen) and limited-field radiotherapy (RT).
Methods
We retrospectively examined a series of HLS treated from 1979 to 1989. We searched for subtle cardiac abnormalities in a subgroup of asymptomatic individuals, who underwent rest and exercise echocardiography at least 20 years after completing their therapies. Their cardiac assessment included physical examination, electrocardiogram (ECG), and resting and postexercise echocardiograms.
Results
On thorough cardiac assessment a mean of 21 years after their diagnosis, none of the 53 unselected asymptomatic HLS showed physical signs or significant ECG abnormalities during or after the stress echo test. Twenty-two (41%) of the 53 patients revealed valvular abnormalities, with mitral regurgitation in 28%, aortic regurgitation in 9%, and both in 4%. No significant myocardial dysfunction as a result of previous combined doxorubicin treatment and chest RT was identified. Only 2 individuals had mild pericardial alterations.
Conclusions
The present study shows that long-term cardiac effects are common in HLS treated with the ABVD regimen and RT. The most frequent complications observed in this sample were essentially coronary artery disease and valvular abnormalities. None of the survivors in this sample showed overt congestive heart failure, a finding in contrast with larger studies.
MertensACLiuQNegliaJPCause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivors Study. J Natl Cancer Inst.2008;100 (19):1368–79.
2.
MöllerTRGarwiczSBarlowLAssociation of the Nordic Cancer Registries; Nordic Society for Pediatric Hematology and Oncology: Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population study in Nordic countries. J Clin Oncol.2001;19 (13):3173–81.
3.
GinsbergJPGoodmanPLeisenringWLong-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer.2004; 42 (7):563–73.
4.
OeffingerKCMertensACSklarCAChronic health conditions in adult survivors of childhood cancer. N Engl J Med.2006; 355 (15):1572–82.
5.
MulrooneyDAYeazelMWKawashimaTCardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivors Study cohort. BMJ.2009;339:b4606.
6.
KremerLCvan der PalHJOffringaMvan DalenECVoûtePAFrequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol.2002;13 (6):819–29.
7.
LipshultzSEAlvarezJAScullyREAnthracycline-associated cardiotoxicity in survivors of childhood cancer. Heart.2008; 94 (4):525–33.
8.
TrachtenbergBHLandyDCFrancoVIAnthracycline-associated cardiotoxicity in survivors of childhood camcer. Pediatr Cardiol.2011;32 (3):342–53.
9.
FullbrightJMReview of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract.20112011:942090.
10.
SteinherzLJSteinherzPGTanCTHellerGMurphyMLCardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA.1991;266 (12):1672–7.
11.
LipshultzSEColanSDGelberRDPerez-AtaydeARSallanSESandersSPLate cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med.1991;324 (12):808–15.
12.
AdamsMJLipsitzSRColanSDCardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotheraphy. J Clin Oncol.2004;22 (15):3139–48.
13.
SchillerNBShahPMCrawfordMRecommendations for quantification of left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommitee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr.1989Sept-Oct; 2(5):358–67.
14.
QuiñonesMAOttoCMStoddardMWaggonerAZoghbiWADoppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr.2002;15 (2):167–84.
15.
NaguehSFAppletonCPGillebertTCRecommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr.2009;22 (2):107–33.
16.
VahanianABaumgartnerHBaxJGuidelines on the management of valvular heart disease. The Task Force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J.2007;28 (2):230–68.
17.
AdamsMJLipshultzSEPathophysiology of anthracycline and radiation associated cardiomyopathies: implication for screening and prevention. Pediatr Blood Cancer.2005;44 (7):600–6.
18.
van der PalHJvan DalenECvan DeldenEHigh risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol.2012; 30 (13):1429–37.
19.
van DalenECvan der PalHJKokWECaronHNKremerLCClinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer.2006; 42 (18):3191–8.
20.
TemmingPQureshiAHardtJLeiperADLevittGAncliffPJWebbDKHPrevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single center in United Kingdom. Pediatr Blood Cancer.2011;56:625–30.
21.
TukenovaMGuiboutCOberlinORole of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol.2010;28 (8):1308–15.
22.
VelensekVMazicUKrzisnikCDemsarDJazbecJJerebBCardiac damage after treatment of childhood cancer: a long term follow-up. BMC Cancer.2008;8:141.
23.
AlemanBMvan den Belt-DuseboutAWDe BruinMLLate cardiotoxicity after treatment for Hodgkin lymphoma. Blood.2007;109 (5):1878–86.
24.
van Leeuwen-SegarceanuEMBosWJDorresteijnLDRensingBJScreening Hodgkin lymphoma survivors for radiotherapy-induced cardiovascular disease. Cancer Treat Rev.2011; 37 (5):391–403.
25.
WethalTLundMBEdvardsenTValvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Brit J Cancer.2009;101 (4):575–81.
26.
HeidenreichPAHancockSLLeeBKMariscalCSSchnittgerIAsymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol.2003;42 (4):743–9.
27.
SorensenKLevittGABullCDorupISullivanIDLate anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer.2003;97 (8):1991–8.
28.
RammelooLAPostmaASobotka-PlojharMALow-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Chilhood Leukemia Study Group. Med Pediatr Oncol.2000;35 (1):13–9.
29.
JarfeltMKujacicVHolmgrenDBjarnasonRLanneringBExercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer.2007;49 (6):835–40.
30.
Guimaraes-FilhoFTanDBragaJRodriguesAWaibPMatsubaraBVentricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines. Am J Cardiol.2007;100 (8):1303–6.
31.
MarchandiseBSchroederEBoslyAEarly detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J.1989;118 (1):92–8.
32.
GanameJClausPEyskensBAcute cardiac functional and morphological changes after anthracycline infusions in children. Am J Cardiol.2007;99 (7):974–7.
33.
Tassan-ManginaSCodoreanDMetivierMTissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr.2006; 7 (2):141–6.
34.
RatheMCarlsenNLOxhøjHLate cardiac effects of anthracycline containing therapy of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer.2007;48 (7):663–7.
35.
ArmstrongGTJoshiVMNessKKComprehensive Echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer. J Am Coll Cardiol.2015;65 (23):2511–22.
36.
YuAFRaikhelkarJZaborECTwo-dimensional speckle tracking echocardiography detects suclinical left ventricular systolic dysfunction among adult survivors of childhood, adolescent and young adult cancer. Biomed Res Int.2016;2016:9363951.
37.
CheungYFChanGCWongSJHaSYLeft ventricular twisting and untwisting motion in childhood cancer survivors. Echocardiography.2011;28:738–45.
38.
ThavendiranathanPGrantADNegishiTPlanaJCPopovicZBMarwickTHReproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotheraphy. J Am Coll Cardiol.2013;61:77–84.
39.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med.1991;325 (5):293–302.
40.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsN Engl J Med.1992;327 (10):685–691.
ArmenianSHHudsonMMMulderRRecommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol.2015;16 (3):123–36.
